Article Text

PDF
OP0097 Autoantibodies Precede Interferon Elevation in Pre-Clinical Lupus
  1. M.E. Munroe1,
  2. D.A. Fife1,
  3. J.M. Robertson1,
  4. Y.D. Zhao2,
  5. B.F. Bruner3,
  6. T.B. Niewold4,
  7. G.C. Tsokos5,
  8. M.P. Keith6,
  9. J.B. Harley7,8,
  10. J.A. James1,9
  1. 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation
  2. 2Biostatistics and Epidemiology, University of Oklahoma Health Science Center, Oklahoma City
  3. 3Biology, Harding University, Searcy
  4. 4Rheumatology, Mayo Clinic, Rochester
  5. 5Rheumatology, Beth Israel Deaconness Medical Center Harvard Medical School, Boston
  6. 6Rheumatology, Uniformed Services University of Health Sciences, Bethesda
  7. 7US Department of Veterans Affairs Medical Center
  8. 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati
  9. 9Medicine and Pathology, University of Oklahoma Health Science Center, Oklahoma City, United States

Abstract

Background Determining processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis would provide insight into the fundamental origins of SLE pathogenesis.

Objectives This study evaluates the temporal relationship between autoantibody production, interferon (IFN) levels and the onset of SLE.

Methods Serial sera from 56 pre-clinical SLE cases leading up to SLE classification (average timespan=4.3 years) and matched healthy controls were obtained from the Department of Defense Serum Repository. Sera samples were tested for autoantibodies (BioPlex2200), IFN-α activity, and soluble inflammatory mediators, including IFN associated chemokines and BLyS (B lymphocyte stimulator). Temporal relationships between IFN activity and autoantibody positivity were determined and confirmed using Path analysis.

Results Serum IFN-α activity scores, as well as IFN-correlated (p<0.001) soluble mediators IFN-γ, IP-10, and BLyS levels increase in patients leading up to SLE disease classification (p≤0.01). IFN activity positive individuals have an increased number of autoantibodies compared to IFN activity negative individuals (p<0.05). Autoantibodies accumulate prior to or concurrent with increases in IFN activity in 84% of IFN positive cases. Of the 3 models of IFN vs. autoantibody positivity determined via Path analysis (autoantibody 1st, IFN activity 1st, or concurrent), autoantibody positivity prior to IFN activity ranked first, irrespective of whether DNA- or RNA-binding autoantibodies were present, as assessed by both Akaike's information criterion (AIC) and root mean square error of approximation (RMSEA).

Conclusions That autoantibodies accumulate prior to the increases in IFN activity levels suggests that the elevated IFN activity observed in SLE patients is a consequence of pre-clinical immune system perturbations.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3402

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.